Anti-HER2 vaccines: The HER2 immunotargeting future?;Vaccination anti-HER2: l'avenir du ciblage immunologique de HER2?

Pathologie Biologie

Volumn 59, Issue 3, 2011, Pages 173-182

  Ladjemi, M Z ^a   Jacot, W ^a   Pelegrin A ^a   Navarro Teulon, I ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Active immunotherapy; Cancer; HER2; Immunoth rapie active

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; TRASTUZUMAB; CANCER ANTIBODY; DNA VACCINE; HER2 NEU DERIVED PEPTIDE (654 662); HER2 PEPTIDE (369 377); HER2 PEPTIDE (369-377); HER2 PROTEIN, HUMAN; HER2-NEU-DERIVED PEPTIDE (654-662); IMMUNOLOGICAL ADJUVANT; PEPTIDE FRAGMENT; RECOMBINANT VACCINE; SUBUNIT VACCINE; TUMOR ANTIGEN;

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG RESEARCH; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; ACTIVE IMMUNIZATION; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DRUG SCREENING; FEMALE; IMMUNOLOGY; METABOLISM; TRANSPLANTATION; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 79958754997     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.04.002     Document Type: Review

References (72)

1. Slichenmyer W.J., Fry D.W. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001, 28(Suppl. 16):67-79.
2. Schmidt M., et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method oftesting. Breast Cancer Res 2005, 7:R256-R266.
3. Martin M., et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100:805-814.
4. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: Prognostic Factor, Predictive factor, and Target for Therapy. Oncologist 1998, 3:237-252.
5. Peoples G.E., et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995, 92:432-436.
6. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
7. Nahta R., Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232:123-138.
8. Berns K., et al. A functional genetic approach identifies the PI3Kpathway as a major determinant oftrastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
9. Cobleigh M.A., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
10. Bengala C., et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006, 94:1016-1020.
11. Disis M.L., et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994, 54:16-20.
12. Fisk B., et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995, 181:2109-2117.
13. Disis M.L., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88:202-210.
14. Huber C.H., Wolfel T. Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 2004, 130:367-374.
15. Dols A., et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003, 14:1117-1123.
16. Dols A., et al. Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother 2003, 26:163-170.
17. Park J.W., et al. Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 2007, 25:3680-3687.
18. Bernhard H., et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 2008, 57:271-280.
19. Sakai Y., et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 2004, 64:8022-8028.
20. Chen Y., et al. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL- 12. Gene Ther 2001, 8:316-323.
21. Chen Z., et al. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther 2002, 9:778-786.
22. Brossart P., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96:3102-3108.
23. Czerniecki B.J., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007, 67:1842-1852.
24. Campbell M., et al. An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression. Cancer Gene Ther 2003, 10:559-570.
25. Sas S., et al. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER- 2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Ther 2008, 15:655-666.
26. Chan T., et al. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu- specific immune responses compared to DNA vaccination. Gene Ther 2006, 13:1391-1402.
27. Viehl C.T., et al. A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol 2005, 12:517-525.
28. Wei W.Z., et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999, 81:748-754.
29. Pilon S.A., Piechocki M.P., Wei W.Z. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 2001, 167:3201-3206.
30. Piechocki M.P., Pilon S.A., Wei W.Z. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001, 167:3367-3374.
31. Wei W.Z., et al. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res 2005, 65:8471-8478.
32. Jacob J., et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006, 240:96-106.
33. Jacob J.B., et al. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory Tcells. Cancer Res 2007, 67:7020-7027.
34. Rovero S., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000, 165:5133-5142.
35. Gallo P., et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005, 113:67-77.
36. Radkevich-Brown O., et al. Genetic regulation ofthe response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res 2009, 69:212-218.
37. Disis M.L., et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002, 20:2624-2632.
38. Disis M.L., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004, 22:1916-1925.
39. Disis M.L., et al. Humoral epitope-spreading following immunization with a HER-2/neu peptide-based vaccine in cancer patients. J Clin Immunol 2004, 24:571-578.
40. Knutson K.L., Schiffman K., Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001, 107:477-484.
41. Butterfield L.H., et al. Determinant spreading associated with clinical response in dendritic cell- based immunotherapy for malignant melanoma. Clin Cancer Res 2003, 9:998-1008.
42. Disis ML, Strickler JH, Wallace D, Goodell V, Salazar G, Higgins D, et al. Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine. ASCO, 2008 [Abstract 3015].
43. Webster DJ, Waisman J, Macleod B, Dela Rosa C, Higgins D, Fintak P, et al. A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab. ASCO, 2006 [Abstract 2528].
44. Holmes J.P., et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008, 26:3426-3433.
45. Mittendorf E.A., et al. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008, 57:1511-1521.
46. Lustgarten J., et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD. 8. Hum Immunol 1997, 52:109-118.
47. Anderson B.W., et al. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 2000, 6:4192-4200.
48. Knutson K.L., et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002, 8:1014-1018.
49. Murray J.L., et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002, 8:3407-3418.
50. Zaks T.Z., Rosenberg S.A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998, 58:4902-4908.
51. Peoples G.E., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005, 23:7536-7545.
52. Peoples G.E., et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008, 14:797-803.
53. Hueman M.T., et al. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat 2006, 98:17-29.
54. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-5218.
55. Mittendorf E.A., et al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 2006, 13:1085-1098.
56. Mittendorf E.A., et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006, 106:2309-2317.
57. Yip Y.L., et al. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001, 166:5271-5278.
58. Dakappagari N.K., et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000, 60:3782-3789.
59. Dakappagari N.K., et al. A chimeric multihuman epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003, 170:4242-4253.
60. Cho H.S., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
61. Garrett J.T., et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007, 178:7120-7131.
62. Riemer A.B., et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004, 173:394-401.
63. Jasinska J., et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 2003, 107:976-983.
64. Wagner S., et al. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multipeptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 2007, 106:29-38.
65. Azuma K., et al. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res Treat 2004, 86:19-29.
66. Limentani, S., Dorval T, White S, Curigliano G, Campone M, Disis N, et al. Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer. ASCO 2005 [Abstract 2520].
67. Kitano S., et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 2006, 12:7397-7405.
68. Kageyama S., et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 2008, 99:601-607.
69. Baral R., et al. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu. Int J Cancer 2001, 92:88-95.
70. Coelho M., et al. Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br J Cancer 2004, 90:2032-2041.
71. Mohanty K., et al. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat 2007, 104:1-11.
72. Pal S., et al. Generation of Her-2/neu vaccine utilizing idiotypic network cascade. Cancer Biol Ther 2007, 6:1916-1925.